Beta Thalassemia Treatment Market Analysis

Therapy (Blood Transfusion, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplant)

Beta thalassemia treatment market from the iron chelation therapy segment is predicted to hold 40% share during the predicted time period. Currently, treating the symptoms of beta thalassemia is the norm rather than trying to find a solution. The majority of the treatments for the condition deal with the iron excess brought on by blood transfusions, as well as fetal hemoglobin-raising drugs, vitamin supplements, and the antioxidant indicaxanthin, which prevents hemoglobin from degrading. It is anticipated that the demand for iron-chelating therapies will present several potentials for business expansion if drugs that are presently in phase II or phase III studies are approved by the FDA.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Based on distribution channel, the hospitals pharmacies segment in the beta thalassemia treatment market is anticipated to hold a significant revenue share during the time period. The segment is anticipated to grow as hospital pharmacies are able to offer patients access to a wide range of medications and other products as well support of healthcare professionals. Furthermore, increasing demand for innovative and effective treatments along with the development of new therapies are boosting the growth of this segment in the projected period. Reblozyl received approval from the U.S. Food and Drug Administration in November 2019 to treat anemia in adult beta-thalassemia patients who require frequent red blood cell transfusions.

Our in-depth analysis of the global beta-thalassemia treatment market includes the following segments: